Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more
Sinocelltech Group Ltd (688520) - Net Assets
Latest net assets as of September 2025: CN¥-730.66 Million CNY
Based on the latest financial reports, Sinocelltech Group Ltd (688520) has net assets worth CN¥-730.66 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.76 Billion) and total liabilities (CN¥4.49 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥-730.66 Million |
| % of Total Assets | -19.43% |
| Annual Growth Rate | 6.69% |
| 5-Year Change | -77.07% |
| 10-Year Change | N/A |
| Growth Volatility | 716.13 |
Sinocelltech Group Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Sinocelltech Group Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual net assets of Sinocelltech Group Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥134.94 Million | +122.27% |
| 2023-12-31 | CN¥-605.81 Million | -150.14% |
| 2022-12-31 | CN¥-242.19 Million | -4.85% |
| 2021-12-31 | CN¥-230.99 Million | -139.26% |
| 2020-12-31 | CN¥588.36 Million | +1590.51% |
| 2019-12-31 | CN¥34.80 Million | +245.98% |
| 2018-12-31 | CN¥-23.84 Million | -114.21% |
| 2017-12-31 | CN¥167.84 Million | +108.81% |
| 2016-12-31 | CN¥80.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sinocelltech Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9587.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥445.34 Million | 316.07% |
| Other Components | CN¥3.51 Billion | 2493.71% |
| Total Equity | CN¥140.90 Million | 100.00% |
Sinocelltech Group Ltd Competitors by Market Cap
The table below lists competitors of Sinocelltech Group Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Success Electronics Ltd
SHE:002289
|
$544.42 Million |
|
Jiuzhitang Co Ltd
SHE:000989
|
$544.45 Million |
|
China Camc Engineering Co Ltd
SHE:002051
|
$544.51 Million |
|
Marfrig Global Foods SA
PINK:MRRTY
|
$544.56 Million |
|
SCG PACKAGING PCL-NVDR
BK:SCGP-R
|
$544.28 Million |
|
Shantou Wanshun Package Material
SHE:300057
|
$544.27 Million |
|
ANTIN INFRASTR.PRT EO 1
F:8ZU
|
$544.18 Million |
|
Suzhou Kingswood Printing Ink Co Ltd
SHE:300192
|
$544.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinocelltech Group Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -599,461,618 to 140,896,888, a change of 740,358,506.
- Net income of 111,951,096 contributed positively to equity growth.
- Dividend payments of 106,083,912 reduced retained earnings.
- Other factors increased equity by 734,491,322.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥111.95 Million | +79.46% |
| Dividends Paid | CN¥106.08 Million | -75.29% |
| Other Changes | CN¥734.49 Million | +521.3% |
| Total Change | CN¥- | % |
Book Value vs Market Value Analysis
This analysis compares Sinocelltech Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 130.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 179.66x to 130.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.22 | CN¥39.40 | x |
| 2017-12-31 | CN¥0.46 | CN¥39.40 | x |
| 2018-12-31 | CN¥-0.06 | CN¥39.40 | x |
| 2019-12-31 | CN¥0.08 | CN¥39.40 | x |
| 2020-12-31 | CN¥1.36 | CN¥39.40 | x |
| 2021-12-31 | CN¥-0.52 | CN¥39.40 | x |
| 2022-12-31 | CN¥-0.54 | CN¥39.40 | x |
| 2023-12-31 | CN¥-1.35 | CN¥39.40 | x |
| 2024-12-31 | CN¥0.30 | CN¥39.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinocelltech Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 79.46%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.46%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 23.31x
- Recent ROE (79.46%) is above the historical average (-258.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -14.56% | -12.37% | 0.23x | 5.06x | CN¥-20.48 Million |
| 2017 | -80.53% | -2357.52% | 0.01x | 2.78x | CN¥-158.82 Million |
| 2018 | 0.00% | -15387.26% | 0.01x | 0.00x | CN¥-451.02 Million |
| 2019 | -2189.55% | -30122.07% | 0.00x | 22.27x | CN¥-798.35 Million |
| 2020 | -120.59% | -217117.79% | 0.00x | 2.82x | CN¥-771.59 Million |
| 2021 | 0.00% | -645.01% | 0.10x | 0.00x | CN¥-844.20 Million |
| 2022 | 0.00% | -50.72% | 0.37x | 0.00x | CN¥-495.33 Million |
| 2023 | 0.00% | -20.98% | 0.69x | 0.00x | CN¥-336.07 Million |
| 2024 | 79.46% | 4.46% | 0.77x | 23.31x | CN¥97.86 Million |
Industry Comparison
This section compares Sinocelltech Group Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinocelltech Group Ltd (688520) | CN¥-730.66 Million | -14.56% | N/A | $544.30 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |